Sulfogel-preparation for treatment of infected wounds in toe region of animals and method of its use
FIELD: veterinary medicine.
SUBSTANCE: preparation for treatment of infected wounds in the toe region of animals, containing dimethyl sulphoxide, methyl cellulose, additionally comprises tylosin tartrate, sulphadimine, trimethoprim in the following ratio of components, wt %: tylosin tartrate - 2-3, sulphadimine - 4-5, trimethoprim - 1-1.5, dimethyl sulphoxide - 10-15, methylcellulose - 3.0-3.5, water - the rest. The claimed method comprises applying the claimed preparation without preliminary wound cleaning. The preparation is applied to the wound with the layer thickness of 2-3 mm, without application of soft dressing. The treated animals are kept for 2-3 hours on the dry surface.
EFFECT: use of claimed group of inventions increases the efficiency of treatment.
4 cl, 7 tbl, 2 ex
The invention relates to the field of veterinary medicine, in particular to the drugs used for the treatment of purulent-necrotic wounds, ulcers, phlegmon, pododermatitis and other pathologies in the toe area of cattle or sheep, caused by reproduction in stripes of different microorganisms, including Mycobacterium microbacteria.
Known drug against microbacteria cattle and respiratory diseases in calves, treatment and prevention of microbacteria cattle and respiratory diseases in calves (RF patent No. 2262936 from 27.20.2005,, IPC A61K 31/70, AR 11/00, OR 31/00), in which the use of tylosin tartrate, gelatin, lanolin by intramuscular injection in the massive muscle group three times, with an interval of 2-3 days.
The disadvantage of this method is that the drug is administered intramuscularly, the products of which are excreted in the milk and long preserved in the meat, which involves grading of milk during treatment, the restriction of the use of meat after slaughter within 8 days after the last injection.
The closest technical solution, selected as a prototype, is the drug Necrohell (RF patent No. 2204997, IPC AC 33/00, 33/34, from 27.05.2003,).
However, used in this drug ingredients cause irritation, burning and pain, toxic, bad move is.
The task of the invention is the expansion of the means for the treatment of infected wounds on the fingers of the animals, including the causative agent of nitrobacteria.
The problem is solved in that the drug for the treatment of wounds on the fingers of animals containing dimethyl sulfoxide and methycellulose, according to the invention additionally contains tylosin tartrate, sulfadimezin trimethoprim in the following ratio of components, wt.%:
|The methylcellulose||of 3.0-3.5|
The problem is solved also by the fact that the mode of administration of the drug for the treatment of infected finger animal drug is applied to the wound without the prior toilet.
The problem is solved also by the fact that the drug is applied with a layer thickness of 2-3 mm
The problem is solved also by the fact that pet animals the treatment put on a dry surface for 2-3 hours.
The drug was prepared as follows.
One kilogram of the drug in enamel container made of 740 ml of distilled water and while stirring slowly added 30 g of methylcellulose and left for 23 to 24 hours for complete dissolution of methylcellulose, periodically stirring and rubbing the lumps. Then the solution of methylcellulose was made alternately with constant stirring 30 g of tylosin tartrate, 50 g sulfadimezina, 15 g of trimethoprim and 150 ml of dimethylsulfoxide. After 2-3 hours of incubation, the ointment again thoroughly mixed and packaged in a container (white plastic bottles with a capacity of 0.5 liters). If you need a larger amount of the drug given amounts fold increase necessary.
To determine the effective formulation prepared 4 variants of the preparation according to the structure (PL.1)
|Component||Recipe 1||Recipe 2||Recipe 3||Recipe 4|
To determine the clinical effectiveness of each recipe picked up 4 groups of 6 animals with wounds in the toe area. On infected wounds inflicted drug tested variants of the formulation and the animal was placed on a dry surface for 2-3 hours. Every 3-4 days this procedure was repeated until the outcome of the disease (recovery or deterioration). therapeutic effect was assessed by the number of recovered animals. The results of therapeutic action options of the drug are given in table.2.
|Table 2||Variant recipe||Treated animals||Recovered a goal.||The effectiveness of treatment, %|
From the results shown in table 2, shows that all experimental animals recovered when the recipe for the version 3 and 4. Because the effect was already in the recipe for the version 3, it was selected for further studies as an effective and less costly. This drug is given the working title of Alfogel.
Next, determine the minimum inhibitory concentration (MIC) of the drug Solifuges compared with the control drug Necrohell against the microorganisms involved in the infection of wounds in the area of the finger as the reference strains and isolates from wounds (table.3).
|The test microbe||MIC, mg/ml|
|Fusobacterium necrophorum strain "YVES"||0,7||1,3|
|Fusobacterium necrophorum (isolate)||0,7||1,1|
|Escherichia coli PBX 25922||5,3||7,7|
|Escherichia coli (isolate)||of 5.4||7,9|
|Staphilococcus aureus ATCC 25923||the 3.8||4,3|
|Staphylococcus aureus (isolate)||4,1||4,5|
|Streptococcus (isolate)||the 3.8||4,3|
As can be seen from table 3, alfogel had inhibitory effect at lower concentrations than necrohell.
Physical properties (color of the drug) Solifuges and Necroses in storage accounted for the us in table 4.
|Medication||The original color||Color during storage (month)|
|Necrohell||Light yellow||Light brown||Brown||Dark-brown||Brown|
As can be seen from table 4, a significant color change Necrophelia begins after 6 months of storage, and it was after 9 and 12 months. Therefore in the following experiments examined therapeutic efficacy of Solifuges and Necroses after different times of storage. The results of clinical work are reflected in table 5.
|Preparation and storage time (m-C)||Recovered a goal.||Efficiency, %||The duration of treatment, days|
|Alfogel - 9||6||6||100,0||12-16|
|Alfogel - 12||6||6||100,00||16-20|
|Necrohell - 9||6||3||50,0||20-24|
|Necrohell - 12||6||2||33,3||24-28|
Thus, the presented data on the physical properties inhibitory concentration and therapeutic efficacy can be concluded that the proposed drug Alfogel has significantly better performance than the drug Necrohell.
In the claimed invention tylosin tartrate is an antibiotic from the macrolide group is used as active against most gram-positive and some gram-negative bacteria, including Fusobacterim spp., Staphylococcus spp., Streptococcus spp., Corynebacterium spp., Clostridiumspp., involved in inflammation. Tylosin is a low-toxic compound. Tylosin is not used for the treatment of men is the antibiotic exclusively for veterinary use, so the risk of cross-resistance of bacterial human pathogens is extremely small. The drug is in contrast to the other antibiotics has a pronounced immunomodulating and immunostimulating properties, which makes its use more efficient.
Known sulfa drug sulfadimezin in combination trimetoprima has a broad spectrum of antibacterial activity and bactericidal effect, in contrast to other sulfonamides (sulfadimetoksin) operating bakteriostaticheski. The combination of these drugs, each of which has a bacteriostatic action, creates a cumulative effect, provides a high bactericidal activity against gram-positive and gram-negative microorganisms, including bacteria resistant to sulfa drugs.
The invention is illustrated by the following examples.
Example 1. Evaluation of therapeutic efficacy of the drug in terms of economy.
In the experiment had 2 groups of 15 animals (experimental and control), selected by the method of randomination is the first animal in the experimental group, the second - in control and so the button until the complete formation of the groups. In the experimental group on the wound inflicted Alfogel, in the control - Necrohell with a lifespan of no more than 3 months. After applying Solifuges animals kept for 2-3 hours on dry surface. In the control group Necrohell inflicted after using the toilet clean out the wound and applied a soft bandage. Re-treatment in both groups was carried out after 4 days. The treatment efficiency was evaluated by the following parameters: duration of treatment, clinical outcome, the percent recovery (table.6).
|Group / Medication||Treated animals||Recovered a goal.||Efficiency, %||The duration of treatment, days|
From the results shown in table 6, it is seen that the treatment Sulfolenes had the advantage in efficiency (100%) and duration of treatment (12-16 days).
Example 2. Determination of therapeutic efficacy of Solifuges without prior toilet wounds (table.7).
|Treatment option||Animals||Recovered a goal.||Efficiency, %||The duration of treatment, days|
|No toilet wound, a layer of 1-2 mm||6||4||66,70||20-24|
|No toilet wound, a layer of 2-3 mm||6||6||100,00||16-20|
|No toilet wound, a layer of 3-4 mm||6||6||100,00||16-20|
|With a toilet, a 2-3 mm layer of soft bandage||6||6||100,00||16-20|
The data in the table.7, show that the effectiveness of treatment without toilet wound was during application of the layer of 2-3 mm and a subsequent increase in the thickness of the layer. Therefore, it is advisable in order to emanate Alfogel layer of 2-3 mm as an effective and low-cost.
Thus, the drug Alfogel for the treatment of infected wounds on the fingers of the animals has a high therapeutic efficacy (100%), easy to prepare and use. Using Solifuges in veterinary practice contributes to the conservation of animals, to prevent economic damage from diseases of the fingers, including microbacteria.
1. Drug for the treatment of infected wounds on the fingers of animals containing dimethyl sulfoxide, methylcellulose, wherein the preparation additionally contains tylosin tartrate, sulfadimezin trimethoprim in the following ratio, wt.%:
|The methylcellulose||of 3.0-3.5|
2. The method of using the drug for the treatment of infected wounds on the fingers of the animal, characterized in that the drug under item 1 is applied without pre-what about the toilet of the wound.
3. The method according to p. 2, characterized in that the preparation is applied to the wound with a layer thickness of 2-3 mm, without blending with a soft bandage.
4. The method according to p. 2, characterized in that the treated animals aged for 2-3 hours on dry surface.
FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to medicine, and concerns a pharmaceutical composition for treating gastroduodenal ulcer in the form of tablets, capsules or gel, containing therapeutic agents and a consistency base applicable for each dosage, wherein the therapeutic agents are as follows: recombinant interferon specified in a group: recombinant interferon alpha, recombinant interferon beta, recombinant interferon gamma; antiseptics; amino acids specified in a group: arginine, histidine, lysine, cysteine, methionine, glutamic acid; and antioxidants specified in a group: beta-carotene, vitamin C, vitamin E.
EFFECT: invention has the integrated body effect promoting faster healing of the mucosal defect accompanying the aggravated gastroduodenal ulcer and preventing recurrences, including by the eradication effect.
6 cl, 5 ex
FIELD: veterinary medicine.
SUBSTANCE: pharmaceutical composition in the form of ointments for treatment of mastitis in cows comprises n-tetradecyltributylphosphonium bromide as active ingredient and petrolatum as an excipient at the ratio of 1:2000.
EFFECT: invention provides a pharmaceutical composition in the form of an ointment, which is new in mechanism of action, effective when applied topically at low therapeutic concentration.
FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to medicine, and concerns a pharmaceutical composition in the form of tablets for oromucosal administration in treating infectious-inflammatory oropharyngeal diseases. The composition contains recombinant interferon specified in a group: recombinant interferon alpha, recombinant interferon beta, recombinant interferon gamma; amino acid specified in a group: arginine, histidine, glycine, glutathione, lysine, methionine, cysteine; an antiseptic, a preserving agent, flavours specified in a group: tea tree oil, eucalyptus leaf oil, mint leaf oil and a consistence base.
EFFECT: invention makes the composition applicable in fragile and frequently ill patients for reducing a disease recurrence.
7 cl, 1 ex
SUBSTANCE: pathogenetic treatment of chronic tonsillitis and/or hypertrophy of palatine tonsils in preschool children suffering from lymphoproliferative syndrome is ensured by the palatine tonsils debridement. An interleukin-1β(IL-1β) level is measured in the palatine tonsils washing. If the measured value is less than 5.8 pg/ml, recombinant interleukin-1β (IL-1β) is to be administered orally by phonophoresis with the use of the Tonsillor MM apparatus. Two courses of 10 procedures every 14 days are performed. The clinical effectiveness is assessed if observing a positive dynamics of IL-1β measured in the palatine tonsils washing 17 and 41 days after the beginning of the immunomodulatory therapy.
EFFECT: higher clinical effectiveness ensured by the differentiated selection of children for carrying out the immunomodulatory therapy, reducing a rate of infectious involvements of the palatine tonsils in the declared group of patients by the pathogenetically reasoned application of recombinant IL-1β.
3 cl, 2 tbl, 1 ex
SUBSTANCE: present invention refers to medicine. The preparation contains the active substance furacilin (nitrofural, 2-[(5-nitro-2-furanyl)methylen]hydrazine carboxamide), the excipient - sodium chloride, a gas-forming mixture, an acidity regulator for reducing pH from 6.5 to 7.5 and a lubricant if needed. The gas-forming mixture consists of an organic acid and sodium hydrocarbonate. According to the method for preparing effervescent tablets of furacilin, furacilin and sodium chloride are milled in a combination; all the ingredients are placed into a mixer, and the prepared mixture is tabletted by direct compression. The antimicrobial therapeutic preparation of furacilin in the form of effervescent tablets is used for septic wounds, bed sores, small skin damages, including scratch marks, abrasions, cuts; infectious-inflammatory oral and throat diseases, including acute tonsillitis, stomatitis, gingivitis and tonsillitis. The effervescent tablets of furacilin are storage-stable for two years and water-soluble at room temperature for 5 minutes.
EFFECT: preparing the antimicrobial therapeutic preparation in the form of the effervescent tablets used for preparing the solution for local and external application.
4 cl, 6 tbl, 3 ex
SUBSTANCE: biologically active additive Laviocard+ is prescribed orally 1 capsule 2 times a day with food for 21 days. That is combined with daily wound irrigations with neutral analyte of anhydrohexitol nucleic acid with leaving a sterile gauze bandage impregnated with neutral analyte of anhydrohexitol nucleic acid in the wound until it is clean. That is followed by daily bandaging with Lavitol cosmetic dihydroquercetin powder applied on the wound surface 1-2 mm thick until the wound is healed.
EFFECT: reduced length of wound healing by stimulating the regeneration processes in tissues.
1 ex, 3 tbl
SUBSTANCE: inorganic clay, represented by sodium-calcium, and/or calcium and/or ferrous forms of montmorillonite, is modified with a water solution of silver nitrate with a concentration 0.16-9.9 wt % in a weight ratio clay:water solution of silver nitrate 1:5. Modification is carried out with mixing from 3 to 7 hours at a temperature in the interval from 10°C to the temperature of boiling. The obtained material is washed with distilled water to pH ≈6-5, until excess of silver nitrate is removed, stood at room temperature and decanted. The material is dried at a temperature of 20-160°C.
EFFECT: obtaining an efficient antibacterial material for traditional and veterinary medicine.
2 tbl, 5 ex
FIELD: veterinary medicine.
SUBSTANCE: agent for prevention of mastitis in dairy cows in the dry period, characterised in that it contains as ingredients the polymer PVP/VA, silicone, polyhexamethylene biguanide, ethyl alcohol, glycerol - as emollient component, gelation agents - triethanolamine and carbopol and purified water in the following ratio of ingredients, %: polymer PVP/VA 9-10; silicone 5-6; ethyl alcohol 35-40; polyhexamethylene biguanide 0.008-0.01; glycerol 5; gelation agents - triethanolamine and carbopol 0.1; purified water - the rest.
EFFECT: method enables to minimise or eliminate the use of chemotherapeutic agents, antibiotics and their derivatives, sulphonamides, nitrofurans and eliminate the side effect of the agent on animal body, as well as to reduce the number of visits of the veterinarian during the dry period of cows, to improve the preventive efficacy.
1 tbl, 3 ex
SUBSTANCE: invention refers to the veterinary science, particularly to substances used in treating purulent-necrotic involvements of bovine's distal extremities, including digital dermatitis. A preparation for treating bovine digital dermatitis in the form of an ointment consists of an excipient, containing an ointment base, and an active ingredient - zinc oxide and copper sulphate in the following proportions, wt %: zinc oxide 9-11, copper sulphate 35-45, the ointment base - the rest.
EFFECT: invention provides higher clinical effectiveness with cost cutting for the ointment preparation.
SUBSTANCE: invention refers to medicine, namely to otorhinolaryngology, and may be used for the preoperative preparation of the patients suffering a perforated nasal septum. Intranasal silicone splints are placed 10 days before the operation. The splint is incised from one side within a perforation border. A 30° endoscope is used to assist a 7-day daily nasal perforation rinsing with chlorhexidine. A suction unit is used to evacuate mucosal secretion; synthomycin ointment is introduced through the incision in the silicone splint to the perforation region. The nasal cavity is irrigated daily with antiseptic and vasoconstrictive preparations. On the 7th day, the intranasal splints are removed.
EFFECT: method enables relieving the mucosal inflammation within the perforation, promotes the prolonged drug retention in the introduction place, ensures avoiding an overlay of a secondary infection, improves the functional state of ciliated epithelium.
SUBSTANCE: invention refers to medicine, namely to surgery, and can be used for treating trophic ulcers and purulonecrotic involvements of lower extremities in diabetic patients. That requires a baseline therapy and a regional fibrinolytic therapy. Conducting the regional fibrinolytic therapy following applying a rubber bandage on the lower one-third of the shin is accompanied by administering Urokinase medac in a dose of 100 thousand units into the heel bone once a day within 5 days.
EFFECT: in the setting of reducing the total dosage of the preparation, the invention enables providing the high concentration of Urokinase medac in a pathological centre, improving microcirculation and metabolic processes in the involved tissues, accelerating the wound healing and reducing the length of hospital admission of the patients suffering from diabetic foot syndrome.
SUBSTANCE: pharmacological composition contains a therapeutic agent and a pharmaceutically acceptable base. As a therapeutic agent, it contains recombinant interferon specified in a group: recombinant interferon alpha, recombinant interferon beta, recombinant interferon gamma, as well as hypromellose, boric acid as an antiseptic, anesthesin or lidocaine as local anaesthetics in the following proportions, g per 1 ml of the mixture: recombinant interferon, IU 100-10,000,000, hypromellose 0.00001-0.5, boric acid 0.00001-0.5, anesthesin or lidocaine 0.00001-0.5, a pharmaceutically acceptable base - the rest. Besides, the pharmaceutical composition contains heparin in an amount of 0.00001-0.5 g; antibiotics specified in a group of: baneocin, levomycin, tetracycline, amoxicilline in an amount of 0.00001-0.5 g. And as a pharmaceutically acceptable base, the pharmaceutical composition contains macrogol 400, or macrogol 1500, or macrogol 4000.
EFFECT: more effective treatment.
4 cl, 9 ex
SUBSTANCE: ulcer region is coated with macroporous hydrogel with the concentration of lightly cross-linked acrylic polymer 0.2-0.6 wt %, gel viscosity 45-85 poises at pH from 7.0 to 7.8. The wound floor is coated with a layer 2-4mm thick, and the wound edges - 1.5-3 mm, while a periulcerous region - 1-3 mm thick.
EFFECT: healing trophic ulcer 5-15 days later and no recurrence for 1-2 years as shown by patient's follow-up.
FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to new idebenone derivatives substituted by carboxylic acid with general formula I wherein R1 represents C2-C22 saccharic acid with a direct or branched chain, while two or more hydroxy groups are independently substituted by C1-C22 carboxylic acid, wherein the term 'branched' refers to one or more groups of a lower alkyl. The invention also refers to a formulation for skin treatment containing the above idebenone derivatives, a method of treating the skin changes by local applications with these idebenone derivatives, as well as to methods of synthesis thereof. When adding the idebenone derivatives according to the present invention into the formulations for local application, they possess the antioxidant action effective in treating the skin changes.
EFFECT: above idebenone derivatives have unexpectedly occurred to be effective in skin treatment, especially in relation to skin tolerance.
20 cl, 1 tbl, 5 ex
SUBSTANCE: method comprises scaling of diploid cells of line M-20 from cryobank of Institute of Poliomyelitis and Viral Encephalitis n.a. MP Chumakov of RAMS from the ampoule of the seed cell bank of 7 passage with obtaining the working cell bank of 16 passage. At that the cells of 20-33 passages, suitable for use in therapeutic and/or diagnostic purposes are produced by culturing in a nutrient medium containing 10% of human fibrinolytic active plasma (FAP), comprising platelet-derived growth factor PDGF in a concentration of from 155 to 342 pg/ml.
EFFECT: invention enables to increase proliferative activity of human fibroblast diploid cells.
2 cl, 2 tbl
FIELD: medicine, pharmaceutics.
SUBSTANCE: invention relates to pharmaceutical industry and represents dermatological cream, intended for local treatment of bacterial skin infections and for healing wounds associated with them, which contains framycetin sulfate and biopolymer, included into cream base, which contains at least one substance from each of the following groups: preservative, primary and secondary emulsifier, selected from the group which contains ketostearyl alcohol, ketomacrogol 1000, polysorbate-80 and Span-80; paraffin as wax-like product, cosolvent, selected from the group, including propylene glycol, hexylene glycol and polyethylene glycol-400; nitric acid or lactic acid and water, with said biopolymer preferably being chitosan.
EFFECT: invention provides higher therapeutic effect.
8 cl, 10 tbl, 2 dwg
FIELD: medicine, pharmaceutics.
SUBSTANCE: present invention refers to medicine, particularly to aspects covering antimicrobial compositions, and described antimicrobial compositions, antimicrobial silicone gel based on the above antimicrobial composition, a wound dressing and methods for preparing them. Among other things, the antimicrobial compositions contain at least one alkenyl- and/or alkynyl-substituted polysiloxane, at least one polysiloxane containing silicone-linked hydrogen atoms, and at least one hydroxylation catalyst, at least one hydrophilic ingredient, at least one silver salt.
EFFECT: invention can be used for preparing a drug preparation to be used in treating burns, scars, bacterial infections, viral infections and/or mycotic infections.
19 cl, 5 dwg, 8 ex, 6 tbl
FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to a topical pharmaceutical preparation for treating inflammatory skin pathologies, preferentially an ischemia-related skin pathology. The above preparation contains a supernatant of normal saline prepared by culturing for at least 1 hour peripheral blood mononuclear cells (PBMC) or their subpopulation in normal saline free from substances promoting the PBMC proliferation and activating the PBMC in the stress-inducing environment. Also, the invention refers to a method for producing and using the above preparation.
EFFECT: invention promotes relieving the symptoms of the inflammatory skin pathologies and the healing process.
20 cl, 18 dwg, 5 ex
SUBSTANCE: biocompatible polymer representing a mixture of Pluronic F127 and carboxymethyl cellulose sodium salt is immobilised on hydroxyapatite nanoparticles. The agent represents the following mixture ratio, wt %: dimethylglucamine salt of chlorine E6 - 0.03-0.45; hydroxyapatite - 0.1-0.3; Pluronic F127 - 2.0-2.5; carboxymethyl cellulose sodium salt - 2.0-2.5; water - the rest. What is also presented is a method of preparing the above agent by immobilising the biocompatible polymer with an included dimethylglucamine salt of chlorine E6 on hydroxyapatite nanoparticles, involving mixing in water of Pluronic F127 with dimethylglucamine salt of chlorine E6, agitating the prepared mixture and solution for 30-40 min and adding carboxymethyl cellulose sodium salt. What is also presented is a method of treating septic wounds of soft tissues combining conventional treatment according to a standard practice and photodynamic therapy. The photodynamic therapy involves coating a wound surface with the presented agent in an amount of 0.05-0.1 g per 1 cm2 of the wound surface, settling for 40-60 min; with the agent coating kept on, the wound surface is exposed to a low-intensity laser light at a wavelength of 663±0.03 nm, power density 1 Wt/cm2 and energy density 25-30 J/cm2.
EFFECT: invention provides the high clinical effectiveness.
8 cl, 2 dwg, 7 ex
SUBSTANCE: lipoaspiration cannula of the diameter of up to 1.2 mm is used to sample primary aspirate from subcutaneous fat of an anterior abdominal wall. The produced aspirate is washed with 5% glucose to prepare a lipid fraction to be diluted with 5% glucose in ratio 1:1 of glucose-fat, agitated to prepare a suspension. The skin is punctured to insert a blunt-ended injection cannula of the diameter of up to 1.2 mm into soft tissues surrounding an ulcer and immediately under an ulcerous defect. The cannula is delivered to an end of each marked beam, and the prepared suspension is administered at the output by removing the cannula gradually by simultaneous pressing on a syringe piston. Up to 5 insertions of the suspensions are fan-shaped from one puncture herewith creating a perifocal cushion of the thickness of up to 0.7 cm. A distance of passage beams shall not exceed 2-3 mm.
EFFECT: higher quality of treatment of this pathology by forming the normotrophic scar tissue by stimulating regional microcirculation.
3 tbl, 1 dwg, 1 ex
FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to medicine and can be used as a hepatotrophic, lipotropic agent in gastroenterology, as well as for treating cardiac and cerebral atherosclerosis, in neurology in the lower extremity artery diseases (endarteritis). The agent contains tabletted powders of diisopropylammonium dichloroacetate, microcrystalline cellulose, lactose and excipients presented by Aerosil, Primogel and calcium stearyl fumarate.
EFFECT: agent possesses no toxicity, has the high adsorption properties, the apparent anti-inflammatory action, and provides metabolism and the liver regeneration.
3 tbl, 2 ex